109 related articles for article (PubMed ID: 10714154)
21. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro.
Shigeta S; Konno K; Baba M; Yokota T; De Clercq E
J Infect Dis; 1991 Feb; 163(2):270-5. PubMed ID: 1846389
[TBL] [Abstract][Full Text] [Related]
22. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes.
Srinivas RV; Connely M; Fridland A
Antiviral Res; 1997 Jun; 35(1):23-7. PubMed ID: 9224958
[TBL] [Abstract][Full Text] [Related]
23. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method.
Kodama E; Shigeta S; Suzuki T; De Clercq E
Antiviral Res; 1996 Jul; 31(3):159-64. PubMed ID: 8811200
[TBL] [Abstract][Full Text] [Related]
24. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
25. Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G; Snoeck R; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):143-51. PubMed ID: 1327785
[TBL] [Abstract][Full Text] [Related]
26. Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.
Dolnak DR; Munguia D; Wiley CA; De Clercq E; Bergeron-Lynn GL; Boscher C; Connor JD; Sherwood C; Capparelli E; Armani R
Invest Ophthalmol Vis Sci; 1992 Apr; 33(5):1557-63. PubMed ID: 1559752
[TBL] [Abstract][Full Text] [Related]
27. The activity of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine (HPMPC) against equine herpesvirus-1 (EHV-1) in cell cultures, mice and horses.
Gibson JS; Slater JD; Field HJ
Antiviral Res; 1992 Sep; 19(3):219-32. PubMed ID: 1332605
[TBL] [Abstract][Full Text] [Related]
28. Effect of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine on the replication and morphogenesis of herpes simplex virus type 1.
Chatterjee S; Burns P; Whitley RJ; Kern ER
Antiviral Res; 1992 Sep; 19(3):181-92. PubMed ID: 1332603
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro.
Baba M; Mori S; Shigeta S; De Clercq E
Antimicrob Agents Chemother; 1987 Feb; 31(2):337-9. PubMed ID: 3566256
[TBL] [Abstract][Full Text] [Related]
30. Activities of various compounds against murine and primate polyomaviruses.
Andrei G; Snoeck R; Vandeputte M; De Clercq E
Antimicrob Agents Chemother; 1997 Mar; 41(3):587-93. PubMed ID: 9055998
[TBL] [Abstract][Full Text] [Related]
31. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski EG; Araullo-Cruz T
Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication.
Neyts J; De Clercq E
Biochem Pharmacol; 1994 Jan; 47(1):39-41. PubMed ID: 8311844
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.
Neyts J; De Clercq E
J Med Virol; 1993 Nov; 41(3):242-6. PubMed ID: 8263505
[TBL] [Abstract][Full Text] [Related]
35. Immunotoxic potential of antiviral drugs: effects of ganciclovir and (S)-1-(3-hydroxy-2-phosphonylmethoxy propyl) cytosine on lymphocyte transformation and delayed-type hypersensitivity responses.
Simecka JW; Patel P; Kern ER
Antiviral Res; 1992 May; 18(1):53-64. PubMed ID: 1416903
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication.
Lin JC; De Clercq E; Pagano JS
Antimicrob Agents Chemother; 1991 Nov; 35(11):2440-3. PubMed ID: 1666500
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
Snoeck R; Lagneaux L; Delforge A; Bron D; Van der Auwera P; Stryckmans P; Balzarini J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):615-9. PubMed ID: 2170136
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
Smee DF; Bailey KW; Sidwell RW
Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells.
Connelly MC; Robbins BL; Fridland A
Biochem Pharmacol; 1993 Sep; 46(6):1053-7. PubMed ID: 8216348
[TBL] [Abstract][Full Text] [Related]
40. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Romanowski EG; Yates KA; Gordon YJ
Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
